Recent developments in enzymatic approaches to obtain ADP-modified peptides by PARP6, PARP3, PARP14, and PARP10 in human and murine diseases are advancing our ability to generate site-specific MAR antibodies, with future application in animal models of cancer and neurodegenerative diseases [29,30,31,32]. This evidence concerns the gene PARP10 and neurodegenerative disease.